RxDoctor Payments DataLook up a doctor →

Ira Thorla, MD

Dermatology · Baton Rouge, LANPI 1730178047

Payments from drug & device makers

$5,638,528in general payments, 2019–2025

Across 3,064 payments — averaging $1840.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Incyte Corporation$2.6M
  • AbbVie$580K
  • Pfizer$436K
  • Biofrontera Bioscience GmbH$426K
  • Eli Lilly$388K
  • Taro Pharmaceuticals USA, Inc.$265K
  • plus $913K from 47 others
$41,595in research payments, 2019–2025

Across 16 payments — averaging $2599.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$40K
  • AbbVie$1K

What the payments were for

  • Consulting fees$7,83325%
  • Speaking & faculty fees$2,3077%
  • Grants$100%
  • Food & beverage$20,76867%
  • Education$10%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,638,528 in reported general payments places this provider in the 95th percentile of 189 dermatology providers in Louisiana.

See all dermatology providers in Louisiana

Medicare billing

Part B allowed, 2024
$141,974
Medicare patients
613
Services billed
3,077

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TremfyaGuselkumab12$159,756
OtezlaApremilast23$114,761
Taltz AutoinjectorIxekizumab14$95,266
Cosentyx Sensoready (2 Pens)Secukinumab12$87,129
Dupixent PenDupilumab18$65,847
Betamethasone Dipropionate330$14,892
Clobetasol Propionate334$12,640
Triamcinolone Acetonide815$6,026
Levocetirizine Dihydrochloride473$5,721
Fluocinonide119$5,124
Ketoconazole287$4,559
Minocycline Hcl232$4,121
Fluorouracil44$2,619
Metronidazole34$1,816
Tretinoin33$1,632

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonTremfya$1,259$159,75612 claims
AmgenOtezla$153,834$114,76123 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 189 dermatology providers in Louisiana.

Other dermatology in Baton Rouge

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →